TransMedics Group and The Trade Desk receive mixed analyst ratings

TransMedics Group, Inc. has received a consensus rating of ‘Hold’ from thirteen analysts covering the stock. The breakdown of recommendations includes six ‘buy’ ratings, six ‘hold’ ratings, and one ‘sell’ rating. Recent analyst activity includes Oppenheimer lowering its rating to ‘market perform’ and Piper Sandler reiterating an ‘overweight’ rating with a $100.00 price target. The company maintains a market capitalization of approximately $3.06 billion.

The Trade Desk has received an average rating of ‘Reduce’ from thirty-nine analysts. Among these, ten analysts recommend selling, twenty-five recommend holding, and four recommend buying. Recent adjustments include Raymond James Financial downgrading the stock to ‘underperform’ and Susquehanna cutting its rating from ‘positive’ to ‘neutral’ while lowering the price target to $14.00. Despite these ratings, some market sentiment suggests potential benefits from growing demand in connected TV advertising.